Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Cancer Cell

Volumn 7, Issue 4, 2005, Pages 387-397

  Levine, Ross L ^a,b   Wadleigh, Martha ^b   Cools, Jan ^c   Ebert, Benjamin L ^b,e   Wernig, Gerlinde ^a   Huntly, Brian J P ^a   Boggon, Titus J ^b   Wlodarska, Iwona ^c   Clark, Jennifer J ^a   Moore, Sandra ^a   Adelsperger, Jennifer ^a   Koo, Sumin ^a   Lee, Jeffrey C ^e   Gabriel, Stacey ^e   Mercher, Thomas ^a   D'Andrea, Alan ^b   Fröhling, Stefan ^a   Döhner, Konstanze ^d   Marynen, Peter ^c   Vandenberghe, Peter ^c   Mesa, Ruben A ^f   Tefferi, Ayalew ^f   Griffin, James D ^b   Eck, Michael J ^b   Sellers, William R ^b,e   Meyerson, Matthew ^b,e   Golub, Todd R ^b,e,g   Lee, Stephanie J ^b   Gilliland, D Gary ^a,b,g   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f MAYO CLINIC   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CYTOGENETICS; DNA SEQUENCE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; HIGH THROUGHPUT SCREENING; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; INFORMATION; INTERNET; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MOLECULAR GENETICS; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 20244369569     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.03.023     Document Type: Article

References (50)

1. J.W. Adamson, P.J. Fialkow, S. Murphy, J.F. Prchal, and L. Steinmann Polycythemia vera: Stem-cell and probable clonal origin of the disease N. Engl. J. Med. 295 1976 913 916
2. J.F. Apperley, M. Gardembas, J.V. Melo, R. Russell-Jones, B.J. Bain, E.J. Baxter, A. Chase, J.M. Chessells, M. Colombat, and C.E. Dearden Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta N. Engl. J. Med. 347 2002 481 487
3. M.O. Arcasoy, B.A. Degar, K.W. Harris, and B.G. Forget Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene Blood 89 1997 4628 4635
4. C.R. Bartram, A. de Klein, A. Hagemeijer, T. van Agthoven, A. Geurts van Kessel, D. Bootsma, G. Grosveld, M.A. Ferguson-Smith, T. Davies, and M. Stone Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia Nature 306 1983 277 280
5. J. Cools, D.J. DeAngelo, J. Gotlib, E.H. Stover, R.D. Legare, J. Cortes, J. Kutok, J. Clark, I. Galinsky, and J.D. Griffin A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N. Engl. J. Med. 348 2003 1201 1214
6. J. Cools, H. Quentmeier, B.J. Huntly, P. Marynen, J.D. Griffin, H.G. Drexler, and D.G. Gilliland The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia Blood 103 2004 2802 2805
7. A.D. D'Andrea, A. Yoshimura, H. Youssoufian, L.I. Zon, J.W. Koo, and H.F. Lodish The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains Mol. Cell. Biol. 11 1991 1980 1987
8. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, P.J. Roberts, M.C. Heinrich, D.A. Tuveson, S. Singer, and M. Janicek Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
9. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
10. S.V. Evans SETOR: Hardware-lighted three-dimensional solid model representations of macromolecules J. Mol. Graph. 11 1993 134 138
11. S. Frohling, R.F. Schlenk, J. Breitruck, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm Blood 100 2002 4372 4380
12. T. Furitsu, T. Tsujimura, T. Tono, H. Ikeda, H. Kitayama, U. Koshimizu, H. Sugahara, J.H. Butterfield, L.K. Ashman, and Y. Kanayama Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product J. Clin. Invest. 92 1993 1736 1744
13. D.G. Gilliland, K.L. Blanchard, J. Levy, S. Perrin, and H.F. Bunn Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction Proc. Natl. Acad. Sci. USA 88 1991 6848 6852
14. O. Gimm, B.E. Niederle, T. Weber, M. Bockhorn, J. Ukkat, M. Brauckhoff, P.N. Thanh, A. Frilling, E. Klar, B. Niederle, and H. Dralle RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome? Surgery 132 2002 952 959
15. T.R. Golub, G.F. Barker, M. Lovett, and D.G. Gilliland Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation Cell 77 1994 307 316
16. J.N. Katz, L.C. Chang, O. Sangha, A.H. Fossel, and D.W. Bates Can comorbidity be measured by questionnaire rather than medical record review? Med. Care 34 1996 73 84
17. R. Kralovics, K. Indrak, T. Stopka, B.W. Berman, J.F. Prchal, and J.T. Prchal Two new EPO receptor mutations: Truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias Blood 90 1997 2057 2061
18. R. Kralovics, Y. Guan, and J.T. Prchal Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera Exp. Hematol. 30 2002 229 236
19. R. Kralovics, D.W. Stockton, and J.T. Prchal Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease Blood 102 2003 3793 3796
20. V. Lacronique, A. Boureux, V.D. Valle, H. Poirel, C.T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O.A. Bernard A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia Science 278 1997 1309 1312
21. M.B. Lamers, A.A. Antson, R.E. Hubbard, R.K. Scott, and D.H. Williams Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine J. Mol. Biol. 285 1999 713 725
22. K. Lindauer, T. Loerting, K.R. Liedl, and R.T. Kroemer Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation Protein Eng. 14 2001 27 37
23. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, and F.G. Haluska Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
24. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
25. C. Mao, M. Zhou, and F.M. Uckun Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia J. Biol. Chem. 276 2001 41435 41443
26. J.I. Martin-Subero, L. Harder, S. Gesk, B. Schlegelberger, W. Grote, J.A. Martinez-Climent, M.J. Dyer, F.J. Novo, M.J. Calasanz, and R. Siebert Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci Int. J. Cancer 98 2002 470 474
27. A.R. Moliterno, W.D. Hankins, and J.L. Spivak Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera N. Engl. J. Med. 338 1998 572 580
28. L.M. Mulligan, J.B. Kwok, C.S. Healey, M.J. Elsdon, C. Eng, E. Gardner, D.R. Love, S.E. Mole, J.K. Moore, and L. Papi Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 1993 458 460
29. M. Nakao, S. Yokota, T. Iwai, H. Kaneko, S. Horiike, K. Kashima, Y. Sonoda, T. Fujimoto, and S. Misawa Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 10 1996 1911 1918
30. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, and T.J. Boggon EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
31. E. Parganas, D. Wang, D. Stravopodis, D.J. Topham, J.C. Marine, S. Teglund, E.F. Vanin, S. Bodner, O.R. Colamonici, and J.M. van Deursen Jak2 is essential for signaling through a variety of cytokine receptors Cell 93 1998 385 395
32. Y.D. Pastore, J. Jelinek, S. Ang, Y. Guan, E. Liu, K. Jedlickova, L. Krishnamurti, and J.T. Prchal Mutations in the VHL gene in sporadic apparently congenital polycythemia Blood 101 2003 1591 1595
33. P. Peeters, S.D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, P. Philip, F. Monpoux, L. Van Rompaey, M. Baens, H. Van den Berghe, and P. Marynen Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia Blood 90 1997 2535 2540
34. J.F. Prchal, and A.A. Axelrad Letter: Bone-marrow responses in polycythemia vera N. Engl. J. Med. 290 1974 1382
35. P. Saharinen, K. Takaluoma, and O. Silvennoinen Regulation of the Jak2 tyrosine kinase by its pseudokinase domain Mol. Cell. Biol. 20 2000 3387 3395
36. J. Schwaller, J. Frantsve, J. Aster, I.R. Williams, M.H. Tomasson, T.S. Ross, P. Peeters, L. Van Rompaey, R.A. Van Etten, and R. Ilaria Jr. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes EMBO J. 17 1998 5321 5333
37. R.S. Schwartz Polycythemia vera-chance, death, and mutability N. Engl. J. Med. 338 1998 613 615
38. T. Schwede, J. Kopp, N. Guex, and M.C. Peitsch SWISS-MODEL: An automated protein homology-modeling server Nucleic Acids Res. 31 2003 3381 3385
39. M. Silva, C. Richard, A. Benito, C. Sanz, I. Olalla, and J.L. Fernandez-Luna Expression of Bcl-x in erythroid precursors from patients with polycythemia vera N. Engl. J. Med. 338 1998 564 571
40. K.M. Smith, R. Yacobi, and R.A. Van Etten Autoinhibition of Bcr-Abl through its SH3 domain Mol. Cell 12 2003 27 37
41. L. Sokol, M. Luhovy, Y. Guan, J.F. Prchal, G.L. Semenza, and J.T. Prchal Primary familial polycythemia: A frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin Blood 86 1995 15 22
42. M. Tartaglia, E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, H. Kremer, I. van der Burgt, A.H. Crosby, A. Ion, and S. Jeffery Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nat. Genet. 29 2001 465 468
43. M. Tartaglia, C.M. Niemeyer, A. Fragale, X. Song, J. Buechner, A. Jung, K. Hahlen, H. Hasle, J.D. Licht, and B.D. Gelb Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia Nat. Genet. 34 2003 148 150
44. The International HapMap Consortium The International HapMap Project Nature 426 2003 789 796
45. J.E. Thompson, R.M. Cubbon, R.T. Cummings, L.S. Wicker, R. Frankshun, B.R. Cunningham, P.M. Cameron, P.T. Meinke, N. Liverton, Y. Weng, and J.A. DeMartino Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor Bioorg. Med. Chem. Lett. 12 2002 1219 1223
46. J. Ware Jr., M. Kosinski, and S.D. Keller A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity Med. Care 34 1996 220 233
47. S.S. Watowich, X. Xie, U. Klingmuller, J. Kere, M. Lindlof, S. Berglund, and A. de la Chapelle Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state Blood 94 1999 2530 2532
48. K. Wilke, B. Duman, and J. Horst Diagnosis of haploidy and triploidy based on measurement of gene copy number by real-time PCR Hum. Mutat. 16 2000 431 436
49. S. Xiao, S.R. Nalabolu, J.C. Aster, J. Ma, L. Abruzzo, E.S. Jaffe, R. Stone, S.M. Weissman, T.J. Hudson, and J.A. Fletcher FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome Nat. Genet. 18 1998 84 87
50. E.D. Zanjani, J.D. Lutton, R. Hoffman, and L.R. Wasserman Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin J. Clin. Invest. 59 1977 841 848